Synopsis
Four factors defined the performance of pharmaceutical companies in the December quarter – sustained price erosion in the US generics market, cost and supply chain inflation eating into the margins, Indian market continuing to be the driver of growth and active pharmaceutical ingredient (API) sales remaining subdued.
ET Intelligence Group: Four factors defined the performance of pharmaceutical companies in the December quarter – sustained price erosion in the US generics market, cost and supply chain inflation eating into the margins, Indian market continuing to be the driver of growth and active pharmaceutical ingredient (API) sales remaining subdued. Given these factors and as the country recovers from Covid-19, the valuations of pharma companies are
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
To read full story, subscribe to ET Prime
Get Unlimited Access to The Economic Times
Super Saver Sale
@ ₹34 per week
Billed annually at
₹2499 ₹1749(30% off)
Already a Member? Sign In now
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Why ?
![]()
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
![]()
Clean experience with
Minimal Ads-
Comment & Engage with ET Prime community ![]()
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
